Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 4 de 4
1.
Clin Chim Acta ; 501: 216-221, 2020 Feb.
Article En | MEDLINE | ID: mdl-31707166

Isovaleric acidemia (IVA) is an inborn error of metabolism caused by deficiency of isovaleryl-CoA dehydrogenase. IVA clinical picture includes gastroenterological and progressive neurological symptoms which can lead to permanent disability and death. Early detection by newborn screening (NBS) and treatment promotes normal development. In this study, clinical summaries, biochemical measurements and targeted next generation sequencing (tNGS) data from the IVD gene were compared in 13 Mexican patients. The main symptoms were vomiting, feeding refusal, abdominal pain, impaired alertness, lethargy, stupor, coma; hypotonia, ataxia, hallucinations, seizures; anemia, neutropenia and pancytopenia. Mean blood concentration of isovalerylcarnintine was above the reference value (0.5 µM) in symptomatic patients (8.78 µM), as well as in the screen positive newborns (2.23 µM). The molecular spectrum of this cohort was heterogeneous, with 14 different variants identified, seven were previously-described, and seven were novel. The most frequent variant was c.158G > C (p.R53P). In this study, we found a long diagnostic delay (average of 44 months). Thus, it is essential to increase physician awareness of this treatable condition. Biochemical IVA NBS accompanied by molecular studies (e.g. tNGS) will permit identification of potentially asymptomatic forms of the disease, and improve genotype-phenotype relationship, management decisions and follow-up.


Amino Acid Metabolism, Inborn Errors/genetics , DNA/genetics , High-Throughput Nucleotide Sequencing , Isovaleryl-CoA Dehydrogenase/deficiency , Sequence Analysis, DNA , Amino Acid Metabolism, Inborn Errors/blood , Biomarkers/blood , Cohort Studies , Delayed Diagnosis , Female , Humans , Infant, Newborn , Isovaleryl-CoA Dehydrogenase/blood , Isovaleryl-CoA Dehydrogenase/genetics , Male , Mexico , Neonatal Screening , Tandem Mass Spectrometry
2.
J Biomol Tech ; 20(5): 253-7, 2009 Dec.
Article En | MEDLINE | ID: mdl-19949697

Identifying genetic variants and mutations that underlie human diseases requires development of robust, cost-effective tools for routine resequencing of regions of interest in the human genome. Here, we demonstrate that coupling Applied Biosystems SOLiD system-sequencing platform with microarray capture of targeted regions provides an efficient and robust method for high-coverage resequencing and polymorphism discovery in human protein-coding exons.


Polymorphism, Genetic , Sequence Analysis, DNA/methods , Base Sequence , Biomedical Technology/methods , Exons , Genetic Variation , Genome, Human , Heterozygote , Homozygote , Humans , Molecular Sequence Data , Mutation , Oligonucleotide Array Sequence Analysis
3.
Genome Res ; 19(9): 1527-41, 2009 Sep.
Article En | MEDLINE | ID: mdl-19546169

We describe the genome sequencing of an anonymous individual of African origin using a novel ligation-based sequencing assay that enables a unique form of error correction that improves the raw accuracy of the aligned reads to >99.9%, allowing us to accurately call SNPs with as few as two reads per allele. We collected several billion mate-paired reads yielding approximately 18x haploid coverage of aligned sequence and close to 300x clone coverage. Over 98% of the reference genome is covered with at least one uniquely placed read, and 99.65% is spanned by at least one uniquely placed mate-paired clone. We identify over 3.8 million SNPs, 19% of which are novel. Mate-paired data are used to physically resolve haplotype phases of nearly two-thirds of the genotypes obtained and produce phased segments of up to 215 kb. We detect 226,529 intra-read indels, 5590 indels between mate-paired reads, 91 inversions, and four gene fusions. We use a novel approach for detecting indels between mate-paired reads that are smaller than the standard deviation of the insert size of the library and discover deletions in common with those detected with our intra-read approach. Dozens of mutations previously described in OMIM and hundreds of nonsynonymous single-nucleotide and structural variants in genes previously implicated in disease are identified in this individual. There is more genetic variation in the human genome still to be uncovered, and we provide guidance for future surveys in populations and cancer biopsies.


Base Pairing , Computational Biology/methods , Genetic Variation , Genome, Human , Ligases , Sequence Analysis, DNA/methods , Africa , Base Sequence , Genomics , Genotype , Heterozygote , Homozygote , Humans , Polymorphism, Single Nucleotide , Reference Standards
4.
Mol Microbiol ; 47(2): 397-409, 2003 Jan.
Article En | MEDLINE | ID: mdl-12519191

The MuA transposase mediates transposition of bacteriophage Mu through two distinct mechanisms. The first integration event following infection occurs through a non-replicative mechanism. In contrast, during lytic growth, multiple rounds of replicative transposition amplify the phage genome. We have examined the influence of gyrase and DNA supercoiling on these two transposition pathways using both a gyrase-inhibiting drug and several distinct gyrase mutants. These experiments reveal that gyrase activity is not essential for integration; both lysogens and recombination intermediates are detected when gyrase is inhibited during Mu infection. In contrast, gyrase inhibition causes severe defects in replicative transposition. In two of the mutants, as well as in drug-treated cells, replicative transposition is almost completely blocked. Experiments probing for formation of MuA-DNA complexes in vivo reveal that this block occurs very early, during assembly of the transposase complex required for the catalytic steps of recombination. The findings establish that DNA structure-based signals are used differently for integrative and replicative transposition. We propose that transposase assembly, the committed step for recombination, has evolved to depend on different DNA /architectural signals to control the reaction outcome during these two distinct phases of the phage life cycle.


Bacteriophage mu/physiology , DNA Gyrase/metabolism , Gene Expression Regulation, Viral , Transposases/metabolism , Virus Integration/physiology , Virus Replication/physiology , Bacteriolysis , DNA Gyrase/genetics , DNA, Viral/biosynthesis , Escherichia coli/virology , Lysogeny , Mutation , Recombination, Genetic , Topoisomerase II Inhibitors
...